The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2015Delivery of Cerebral Dopamine Neurotrophic Factor with Microbubbles and MRI-guided Focused Ultrasound (Supplement)
Promising Outcomes of Original Grant:
We achieved our key goal of non-invasive, targeted delivery of therapeutic doses of CDNF drug to the brain regions affected by Parkinson’s [striatum (ST) and... -
Research Grant, 2015Investigation of SNCA Mosaicism in Brain in Parkinson's Disease
Objective/Rationale:
In most cases, the cause of Parkinson’s disease (PD) is unknown. Testing blood for genetic mutations (DNA changes) known to cause PD is usually negative, particularly... -
Target Validation, 2015Utilizing Transcriptional Pathways to Enhance Mitochondrial Health in Models of Parkinson’s Disease
Objective/Rationale:
Neurons of the substantia nigra are particularly vulnerable to cell death in Parkinson’s disease (PD). One potential contributing factor is dysfunction of mitochondria... -
Target Validation, 2015Modulating Aging-controlling Pathways in Pre-clinical models of Parkinson’s Disease
Objective/Rationale:
Because of its unknown etiology and its link to aging, Parkinson’s disease is often seen as a stochastic and pathological acceleration of aging. Using a high-content... -
Research Grant, 2015Unified Dyskinesia Rating Scale: Application for FDA Designation as a Preferred Scale for Assessing Dyskinesia in Parkinson’s Disease
Study Rationale:
Several scales are available for the rating of dyskinesia in Parkinson’s disease, and the designation of a single preferred scale for studies of new treatments will allow different... -
Target Validation, 2015NLRP3 Inflammasome in Parkinson's Disease
Objective/Rationale:
The goal of this proposal is to validate the NLRP3 inflammasome as a therapeutic target in Parkinson’s disease. Unlike circulating inflammatory mediators whose complex...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.